We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
-6.72%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$647M
AUM Growth
-$83.7M
Cap. Flow
-$10M
Cap. Flow %
-1.55%
Top 10 Hldgs %
49.16%
Holding
110
New
21
Increased
23
Reduced
14
Closed
30

Top Buys

Rank Stock Value
1
SNY icon
Sanofi
SNY
+$30.2M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$24M
3
NVO
Novo Nordisk
NVO
+$22.8M
4
PTCT icon
PTC Therapeutics
PTCT
+$13.5M
5
GILD icon
Gilead Sciences
GILD
+$13.4M

Top Sells

Rank Stock Value
1
AZN icon
AstraZeneca
AZN
+$31.8M
2
GSK icon
GSK
GSK
+$20M
3
ALXN
Alexion Pharmaceuticals
ALXN
+$19.3M
4
VRNT
Verint Systems
VRNT
+$15.6M
5
BLUE
bluebird bio
BLUE
+$9.54M

Sector Composition

Rank Sector Weight
1 Healthcare 74.15%
2 Technology 11.83%
3 Industrials 2.25%
4 Consumer Discretionary 1.19%
5 Communication Services 0.79%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PHXM
76
DELISTED
PHAXIAM Therapeutics S.A.. American Depositary Shares
PHXM
$523K 0.08%
11,784
-120
-1% -$6.82K
CUE icon
77
Cue Biopharma
CUE
$113M
$422K 0.07%
1,667
– –
MRSN
78
DELISTED
Mersana Therapeutics
MRSN
$316K 0.05%
8,000
– –
TUFN
79
DELISTED
Tufin Software Technologies Ltd.
TUFN
$201K 0.03%
+12,231
New +$251K
CLRB icon
80
Cellectar Biosciences
CLRB
$20.5M
$175K 0.03%
292
– –
AAP icon
81
Advance Auto Parts
AAP
$3.35B
– –
-17,400
Closed -$2.68M
AUTL
82
Autolus Therapeutics
AUTL
$407M
– –
-177,546
Closed -$2.86M
AZN icon
83
AstraZeneca
AZN
$263B
– –
-385,000
Closed -$31.8M
BLUE
84
DELISTED
bluebird bio
BLUE
– –
-5,790
Closed -$9.54M
BNTC icon
85
Benitec Biopharma
BNTC
$402M
– –
-157
Closed -$30K
CAMT icon
86
Camtek
CAMT
$6.18B
– –
-417,459
Closed -$3.53M
GSK icon
87
GSK
GSK
$104B
– –
-400,000
Closed -$20M
IFF icon
88
CALL
International Flavors & Fragrances
IFF
$20.2B
– –
-63,500
Closed -$9.21M
IFF icon
89
International Flavors & Fragrances
IFF
$20.2B
– –
-30,000
Closed -$4.35M
INDP icon
90
Indaptus Therapeutics
INDP
$172M
– –
-277
Closed -$2.69M
KZR
91
DELISTED
Kezar Life Sciences
KZR
– –
-6,920
Closed -$534K
MGIC
92
DELISTED
Magic Software Enterprises
MGIC
– –
-185,288
Closed -$1.66M
QURE icon
93
CALL
uniQure
QURE
$3.03B
– –
-265,000
Closed -$20.7M
RDWR icon
94
Radware
RDWR
$1.1B
– –
-102,277
Closed -$2.53M
REGN icon
95
Regeneron Pharmaceuticals
REGN
$78.5B
– –
-30,000
Closed -$9.39M
RGNX icon
96
Regenxbio
RGNX
$620M
– –
-95,564
Closed -$4.91M
SGMO
97
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
– –
-281,291
Closed -$3.03M
SRPT icon
98
CALL
Sarepta Therapeutics
SRPT
$1.57B
– –
-120,000
Closed -$18.2M
SYRE icon
99
Spyre Therapeutics
SYRE
$8.54B
– –
-7,488
Closed -$1.28M
TEVA icon
100
Teva Pharmaceuticals
TEVA
$40.8B
– –
-793,834
Closed -$6.08M
1 2 3
4
5

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q3 2019 Portfolio in Review

As of Q3 2019, Sphera Funds Management held 110 positions worth $647M, down 11% from $731M the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Sphera Funds Management's Q3 2019 filing shows 21 new, 23 increased, 14 reduced and 30 closed positions. Its largest new stake was Sanofi: 700,000 shares worth $32.4M. The largest sale was AstraZeneca, an estimated $31.8M.

By sector, the portfolio is most concentrated in Healthcare at 74% of assets, up from 70% a quarter earlier, followed by Technology and Industrials.

  • Sphera Funds Management's largest Q3 2019 buy was Sanofi: 700,000 shares worth $32.4M.
  • Sphera Funds Management added most to Sarepta Therapeutics in Q3 2019, an estimated $24M increase.
  • Sphera Funds Management's biggest Q3 2019 reduction was Alexion Pharmaceuticals, cutting an estimated $19.3M.
  • Sphera Funds Management fully exited AstraZeneca in Q3 2019, selling an estimated $31.8M.
  • Sphera Funds Management's ten largest holdings make up 49% of its $647M portfolio in Q3 2019.
  • Sphera Funds Management opened 21 new positions and closed 30 in Q3 2019.
  • Sphera Funds Management's portfolio value fell 11% quarter-over-quarter to $647M.

Based on Sphera Funds Management's 13F filing for Q3 2019, filed 14 Nov 2019.